42 results about "Aberrant tissue" patented technology

Light is administered during photodynamic therapy (PDT) for an extended period of time at a plurality of sites distributed within the abnormal tissue of a tumor. A clinical study has shown that a substantially greater volume of abnormal tissue in a tumor is destroyed by the extended administration of light therapy from a plurality of probes than would have been expected based upon the teaching of the prior art. In this process, a plurality of light emitting optical fibers or probes are deployed in a spaced-apart array. After a photoreactive agent is absorbed by the abnormal tissue, the light therapy is administered for at least three hours. The greater volume of necrosis in the tumor is achieved due to one or more concomitant effects, including: the inflammation of damaged abnormal tissue and resultant immunological response of the patient's body; the diffusion and circulation of activated photoreactive agent outside the expected fluence zone, which is believed to destroy the abnormal tissue; a retrograde thrombosis or vascular occlusion outside of the expected fluence zone; and, the collapse of the vascular system that provides oxygenated blood to portions of the tumor outside the expected fluence zone. In addition, is possible that molecular oxygen diffusing and circulating into the expected fluence zone is converted to singlet oxygen during the extended light therapy, causing a gradient of hypoxia and anoxia that destroys the abnormal tissue outside the expected fluence zone.

The present invention, in one aspect, relates to a method for examining a target for tumors or lesions using what is referred to as “Early Increase in microvascular Blood Supply” (EIBS) that exists in tissues that are close to, but are not themselves, the abnormal tissue and in tissues that precede the development of such lesions or tumors. While the abnormal tissue can be a lesion or tumor, the abnormal tissue can also be tissue that precedes formation of a lesion or tumor, such as a precancerous adenoma, aberrant crypt foci, tissues that precede the development of dysplastic lesions that themselves do not yet exhibit dysplastic phenotype, and tissues in the vicinity of these lesions or pre-dysplastic tissues.

An optical system and apparatus for the diagnosis of a biological sample is disclosed. An embodiment of the apparatus includes an optical probe, a probe head distally connectable to the optical probe, the optical probe further comprising at least one optical element for applying an electromagnetic radiation of a first wavelength to the biological sample, and one or more collection elements positioned proximate the at least one optical element; and an analyzer for analyzing a signal received from the biological sample by the one or more collection elements.

A method and system are provided for determining a condition of a selected region of tissue to facilitate the location of surgical resection margins. Electropotential and impedance are measured at one or more locations in an area of the body where tissue is to be removed. An agent may be introduced into the region of tissue to enhance electrophysiological characteristics of that tissue. The condition of the tissue is measured by electropotential and impedance profile. Differences in the profile are used to determine the borders between normal and abnormal tissue so as to facilitate what tissue to resect. Methods and apparatus are also disclosed to determine the efficacy of various therapies.

The present invention, in one aspect, relates to a method of and apparatus for examining a target for tumors or lesions using what is referred to as ''Early Increase in microvascular Blood Supply'' (EIBS) that exists in tissues that are close to, but are not themselves, the abnormal tissue and in tissues that precede the development of such lesions or tumors. While the abnormal tissue can be a lesion or tumor, the abnofmal tissue can also be tissue that precedes formation of a lesion or tumor, such as a precancerous adenoma, aberrant crypt foci, tissues that precede the development of dysplastic lesions that themselves do not yet exhibit dysplastic phenotype, and tissues in the vicinity of these lesions or pre-dysplastic tissues.

The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.

In a light-directed method of identifying abnormal mucosal tissue, any suspect sites revealed by a light that selectively aids in visualizing abnormal tissue are marked with a dye facilitate further evaluation of the suspect tissue.

The visibility of abnormal tissue under light having wavelength peaks which selectively identify abnormal tissue is enhanced in the presence of normal ambient light by viewing the tissue through lens which transmit the wavelength peaks but block transmission of other wavelengths.

The invention discloses a paraffin-embedded tissue sample processing method and a kit for tumor prognosis evaluation. The method comprises the following steps: obtaining a cell nucleus monolayer from a paraffin-embedded tumor tissue sample, dyeing the cell nucleus by using a dyeing reagent, and collecting an image by using a digital pathological scanning analysis system. The content of cell DNA in the abnormal tissue is detected through image analysis of the gray scale and the IOD value of the cell nucleus, and the DNA ploidy is reflected; through image analysis of cell nucleus textures, chromatin structures are quantified, and the structures comprehensively reflect gene changes and epigenetics changes. According to the method, the combined quantitative analysis of two prognosis risk factors is realized on the paraffin-embedded tissue sample through one-time sampling and one-time processing flow by utilizing a digital pathological scanning analysis system, and the analysis result can be used for prognosis evaluation of a patient, so that the efficiency and the accuracy of evaluation work are greatly improved, and reasonable medication is guided.

The invention discloses a reagent fixed-point release method based on ultrasonic microbubble radiography, which relates to the technical field of image processing, and comprises the following steps: performing tissue injection containing specific reagent microbubbles according to the type of abnormal tissues; the supermolecule image of the whole tissue is obtained through high-frequency ultrasonic waves; according to the supramolecular imaging, using the convolutional neural network trained by the image corresponding to the abnormal tissue to perform identification determination and region extraction of the abnormal tissue; focusing of low-frequency ultrasonic waves is carried out according to the area where the abnormal tissue is located; microbubbles in the area where the abnormal tissue is located are burst through the focused low-frequency ultrasonic waves, and specific reagents carried by the microbubbles are released. According to the method, after the supramolecular image is obtained through the high-frequency ultrasonic waves, the edge of the abnormal tissue is defined through the convolutional neural network model, and the ultrasonic waves are changed into low frequency to perform fixed-point microbubble burst control, so that abnormal tissue structure screening and repairing are combined, and the variation degree of the abnormal tissue can be judged.